Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
TERT and prostate cancer are reported together in 2 articles.
Gene
TERT
- HGNC
- HGNC:11730
48articles
48mentions
2variants with confirmed gene link
Most co-reported phenotypes (articles)
thyroid cancer 25breast cancer 2colorectal cancer 2diabetes mellitus 2endometrial cancer 2leukemia 2prostate cancer 2hypertension 1
Reported variants (articles · ClinVar status)
Phenotype
Prostate cancer
218articles
218mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Genomic profiling of urological malignancies using tissue-based next generation sequencing.
PMID 40410007 | DOI 10.1016/j.urolonc.2025.04.011 · Urologic oncology · 2025 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TERT | “For instance, renal cell carcinoma frequently harbors alterations in VHL, PBRM1, and BAP1, influencing therapeutic responses, while urothelial carcinoma is characterized by FGFR3 mutations and TERT promoter alterations, which have implications for targeted therapy.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Prostate cancer commonly involves TMPRSS2-ERG fusions and BRCA2 mutations, affecting treatment strategies, and penile squamous cell carcinoma follows distinct HPV-dependent and HPV-independent pathways, with mutations in TP53 and CDKN2A genes.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | VHL | “For instance, renal cell carcinoma frequently harbors alterations in VHL, PBRM1, and BAP1, influencing therapeutic responses, while urothelial carcinoma is characterized by FGFR3 mutations and TERT promoter alterations, which have implications for targeted therapy.” | 0.98 | hgnc_dict_v1 |
| gene | PBRM1 | “For instance, renal cell carcinoma frequently harbors alterations in VHL, PBRM1, and BAP1, influencing therapeutic responses, while urothelial carcinoma is characterized by FGFR3 mutations and TERT promoter alterations, which have implications for targeted therapy.” | 0.98 | hgnc_dict_v1 |
Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
PMID 31669704 | DOI 10.1016/j.ygeno.2019.09.017 · Genomics · 2020 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TERT | “Sanger Sequencing and immunohistochemistry was employed to investigate the TERT promoter mutations and TERT protein expression with their association to clinicopathological characteristics in over 2200 samples of Middle Eastern origin from 13 different types of cancers.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | breast cancer | “The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | colorectal cancer | “The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).” | 0.98 | phenotype_alias_lexicon_v2 |